We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience.
- Authors
Autore, Francesco; Fresa, Alberto; Innocenti, Idanna; Tomasso, Annamaria; Morelli, Francesca; Corbingi, Andrea; Sorà, Federica; Laurenti, Luca
- Abstract
Its efficacy and safety in combination with chlorambucil (Chl) in patients with treatment-naïve chronic lymphocytic leukemia (CLL) and comorbidities were demonstrated in the CLL11 study by improved progression-free survival (PFS) and overall survival (OS) compared with Chl plus rituximab (R) or Chl alone[[2]], leading to the FDA approval for its use in combination with Chl in patients with previously untreated CLL in 2013. Correlation of clinical characteristics of unfit chronic lymphocytic leukemia (CLL) patients treated with obinutuzumab-chlorambucil (Chl-G).
- Subjects
ANTIBODY-dependent cell cytotoxicity; CHRONIC lymphocytic leukemia; BLOOD cell count
- Publication
Hematological Oncology, 2019, Vol 37, Issue 5, p641
- ISSN
0278-0232
- Publication type
letter
- DOI
10.1002/hon.2684